Insmed, Inc. $INSM Shares Bought by Danske Bank A S

Key Points

• Danske Bank A S boosted its stake in Insmed by 4,494.1% in Q4 to 110,258 shares (about 0.05% of the company) worth roughly $19.19 million.
• Insmed posted an EPS miss of -$1.54 vs. -$1.07 expected, while revenue rose 152.6% year‑over‑year and was essentially in line with estimates.
• Company insiders have sold 179,777 shares (≈$28.25M) in the last three months — including COO Roger Adsett’s sale of 88,060 shares at about $164.63 — even as analysts maintain a consensus Buy rating with a $213.23 average target.

Danske Bank A S boosted its holdings in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 4,494.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 110,258 shares of the biopharmaceutical company's stock after acquiring an additional 107,858 shares during the period. Danske Bank A S owned about 0.05% of Insmed worth $19,189,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. EULAV Asset Management bought a new stake in shares of Insmed during the third quarter valued at approximately $12,961,000. Artisan Partners Limited Partnership lifted its holdings in Insmed by 49.0% in the third quarter. Artisan Partners Limited Partnership now owns 4,937,683 shares of the biopharmaceutical company's stock valued at $711,076,000 after buying an additional 1,623,342 shares during the period. Atika Capital Management LLC acquired a new position in Insmed in the third quarter valued at approximately $13,681,000. Nisa Investment Advisors LLC lifted its holdings in Insmed by 374.6% in the third quarter. Nisa Investment Advisors LLC now owns 10,466 shares of the biopharmaceutical company's stock valued at $1,507,000 after buying an additional 8,261 shares during the period. Finally, Nordea Investment Management AB acquired a new position in Insmed in the fourth quarter valued at approximately $3,492,000.

Insmed Trading Down 2.3%

INSM opened at $133.26 on Friday. The firm's fifty day moving average is $147.89 and its two-hundred day moving average is $166.21. The company has a debt-to-equity ratio of 0.76, a quick ratio of 3.54 and a current ratio of 3.83. The firm has a market cap of $28.76 billion, a PE ratio of -20.79 and a beta of 0.90. Insmed, Inc. has a twelve month low of $63.81 and a twelve month high of $212.75.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.The company's revenue for the quarter was up 152.6% on a year-over-year basis. During the same quarter last year, the business posted ($1.32) earnings per share. Equities research analysts anticipate that Insmed, Inc. will post -2.51 EPS for the current year.

Insiders Place Their Bets

In other Insmed news, COO Roger Adsett sold 88,060 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total value of $14,497,317.80. Following the sale, the chief operating officer directly owned 106,810 shares in the company, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Michael Alexander Smith sold 19,638 shares of the stock in a transaction on Monday, March 30th. The stock was sold at an average price of $150.98, for a total transaction of $2,964,945.24. Following the completion of the sale, the insider owned 51,871 shares in the company, valued at approximately $7,831,483.58. This trade represents a 27.46% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 179,777 shares of company stock worth $28,252,720. Company insiders own 2.10% of the company's stock.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Wells Fargo & Company cut their price objective on shares of Insmed from $208.00 to $175.00 and set an "overweight" rating on the stock in a report on Monday, March 23rd. Raymond James Financial initiated coverage on shares of Insmed in a report on Friday, April 10th. They issued an "outperform" rating and a $200.00 price objective on the stock. Barclays increased their price objective on shares of Insmed from $231.00 to $237.00 and gave the company an "overweight" rating in a report on Wednesday, April 1st. Morgan Stanley upgraded shares of Insmed from an "equal weight" rating to an "overweight" rating and increased their price objective for the company from $166.00 to $212.00 in a report on Monday, March 30th. Finally, Leerink Partners increased their price objective on shares of Insmed from $210.00 to $215.00 and gave the company an "outperform" rating in a report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $213.23.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.